1. Hsia J et al. J Am Coll Cardiol 2011;57:1666-75

2. Baseline Characteristics by Treatment Group and Attained LDL-C Hsia J et al. J Am Coll Cardiol 2011;57:1666-75

3. Independent Predictors of Attaining LDL-C <50 mg/dl at Any Visit Among Rosuvastatin-Allocated Patients Hsia J et al. J Am Coll Cardiol 2011;57:1666-75

4. Cardiovascular Events and All-Cause Mortality by Baseline LDL-C Level Hsia J et al. J Am Coll Cardiol 2011;57:1666-75

5. Time to Occurrence of Major Cardiovascular Events According to Treatment Group and Achieved LDL-C Concentrations Hsia J et al. J Am Coll Cardiol 2011;57:1666-75

6. Primary Endpoint in Pre-Specified Subgroups Within JUPITER Trial, Stratified by Achieved LDL-C Hsia J et al. J Am Coll Cardiol 2011;57:1666-75

7. Fully-Adjusted Hazard Ratios for Incident Cardiovascular Events and All-Cause Mortality According to Treatment Group and Achieved Concentrations of LDL-C Hsia J et al. J Am Coll Cardiol 2011;57:1666-75

8. Numbers and Rates (per 100 Person-Years) of Treatment-Emergent Adverse Events by Treatment Group and Attained LDL-C Hsia J et al. J Am Coll Cardiol 2011;57:1666-75

9. ALT or CK Elevation, Proteinuria, or Hematuria at Any Follow-Up Visit by Treatment Assignment and Attained LDL-C Hsia J et al. J Am Coll Cardiol 2011;57:1666-75

10. Relation of Major Cardiovascular Event Rate to LDL-C at 1 Year in Primary Prevention Trials Hsia J et al. J Am Coll Cardiol 2011;57:1666-75